Companion gene mutations and their clinical significance in AML with double mutant CEBPA

Yang Zhang,Fang Wang,Xue Chen,Yu Zhang,Mingyu Wang,Hong Liu,Wen Teng,Panxiang Cao,Daijing Nie,Xiaoli Ma,Tong Wang,Peihua Lu,Hongxing Liu

DOI: https://doi.org/10.1038/s41417-019-0133-7

IF: 5.854

2019-09-03

Cancer Gene Therapy

Abstract:Acute myeloid leukemia (AML) with double mutant <i>CEBPA</i> (<i>CEBPAdm</i>) is generally associated with favorable prognosis, but the heterogeneity still blatant and needs further exploration. We aimed to comprehensively analyze the companion genetic abnormalities and their clinical significance in AML patients with <i>CEBPAdm</i>. By performed targeted amplicon sequencing of 58 genes in specimens at the time of initial diagnosis of 609 AML patients, we identified 76 cases (12.5%) were <i>CEBPAdm</i>, and 88.2% of them also carry other gene mutations. There were more additional gene mutations, especially more epigenetic modifiers gene mutations in <i>CEBPAsm</i> than <i>CEBPAdm</i> cases, while <i>GATA2</i>, <i>CSF3R</i>, <i>JAK3</i>, and <i>KIT</i> mutations were exclusively betide in <i>CEBPAdm</i> but not <i>CEBPAsm</i>. Mutations of tyrosine kinase genes confer to adverse prognostic in karyotype normal <i>CEBPAdm</i> AML and provide potential therapeutic targets. The incidence of germline <i>CEBPA</i> mutation in <i>CEBPAdm</i> cases was 5.3% (4/76), including one C-terminal mutation. Deciphering the mutation spectrum of <i>CEBPAdm</i> AML could facilitate an in-depth understanding of the pathogenesis and refine the prognostic classification of this disease entity.

oncology,genetics & heredity,medicine, research & experimental,biotechnology & applied microbiology